Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molidustat versus darbepoetin alfa for maintenance treatment of anemia in non-dialysis chronic kidney disease
2013-001192-21Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2013
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in anemia of chronic kidney disease comparing Molidustat with Darbepoetin alfa (2 arms). Primary endpoint: Change in hemoglobin from baseline to the average during the last 4 weeks of treatment. Started Sep 2013; status: completed.
02
Drugs
molidustatdarbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2013-001192-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001192-21.